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Abstract: The death rate of patients with ST-segment elevation myocardial infarction (STEMI)
remains substantial. Fondaparinux is a synthetic selective Factor Xa inhibitor with a high
efficacy and good safety, in terms of bleeding risk, in the prevention and treatment of venous
thromboembolism, and in the treatment of non-ST elevation acute coronary syndromes
(OASIS-5). The OASIS-6 trial was a randomized, double-blind trial comparing fondaparinux
2.5 mg once daily with standard therapy, either placebo or unfractionated heparin according
to the indication, in 12 092 patients with STEMI. At day 30, fondaparinux significantly reduced
the occurrence of the primary efficacy outcome (death or recurrent myocardial infarction) by
14% (p=0.008). Consistent reductions in both death and recurrent MI were observed at 6-
month follow-up. The benefits were significant in patients who received no reperfusion therapy
or a thrombolytic agent, but not in patients undergoing primary percutaneous coronary
interventions. There was a trend (p=0.13) towards fewer severe bleeds in the fondaparinux
group (1.0% vs 1.3% in the control group). In conclusion, fondaparinux significantly reduced
mortality without increasing severe bleeding in patients with STEMI. Overall, the data from
the OASIS studies showed that fondaparinux 2.5 mg may represent a new anticoagulant
standard in patients with acute coronary syndromes.
Keywords: acute myocardial infarction, anticoagulant, arterial thrombosis, fondaparinux,
heparin, thrombolytic
ST-segment elevation myocardial infarction (STEMI) is due to the occlusion of
coronary arteries by a thrombus at the site of atherosclerotic plaque rupture (Theroux
and Fuster 1998). The aim of the treatments is to restore blood flow though the
blocked coronary vessels, either pharmacologically with thrombolytic drugs or
mechanically by percutaneous coronary intervention (PCI). This reperfusion therapy,
central to the treatment of STEMI, is associated with the administration of adjunctive
treatments designed to preclude the reocclusion of the coronary arteries. These
treatments include antiplatelet agents (aspirin, clopidogrel, and/or antagonists of
platelet glycoprotein IIb-IIIa), and anticoagulants (unfractionated heparin [UFH] or
low-molecular-weight heparin) (van de Werf et al 2003; Antman et al 2004).
Nevertheless, despite the availability of these therapies, one third of STEMI patients
die within 24 hours of the onset of STEMI (Antman et al 2004), 8%–10% of patients
die or suffer reinfarction during their hospitalization (Antman et al 2004), and 6%–
7% die within one month of discharge (van de Werf et al 2003). These results may be
due to the limited antithrombotic efficacy of the primary treatments, but also to their
effects on bleeding. Indeed, recent data showed that short-term bleeding events were
associated with long-term mortality (Moscucci et al 2003; Spiess et al 2004; Rao et
al 2005, 2006; Eikelboom et al 2006). For example, the in-hospital death rate was
22.8% in STEMI patients with major bleeding compared with 7.0% in those without
major bleeding (Moscucci et al 2003). Discontinuation of antithrombotic agents in
the event of bleeding, or the deleterious effect of transfusion therapy, may play a role
in these adverse outcomes. Consequently, the challenge for new antithrombotic
strategies is to be more effective without increasing bleeding risk. This manuscript
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will focus on anticoagulants, and notably fondaparinux,
which showed substantial benefit in a large phase III trial in
patients with STEMI (Yusuf et al 2006b). Since
fondaparinux is a new drug, we will also present data
obtained in other medical and surgical settings with this
anticoagulant.
Current recommendations for the
use of anticoagulants in patients
with STEMI
UFH is the anticoagulant drug currently recommended in
patients with STEMI (van de Werf et al 2003; Antman et al
2004), this drug showing a marginal benefit for preventing
death in a meta-analysis of trials with or without UFH
(Collins et al 1997). However, the use of UFH is not
recommended in all clinical situations. Its benefit depends
mainly on the other therapeutic strategies used in
combination with this drug. Thus, North American and
European guidelines recommend the use of intravenous
UFH in patients undergoing reperfusion therapy with fibrin-
specific thrombolytic agents (van de Werf et al 2003;
Antman et al 2004). The dose is to be adjusted to maintain
the activated partial thromboplastin time (aPTT) at 1.5–2.0
times the control value. The duration of treatment
recommended is 48 hours; this duration may be adapted
according to the clinical characteristics of the patient. On
the other hand, the use of UFH in patients undergoing
reperfusion therapy with a non-fibrin-specific thrombolytic
drug is judged to be “reasonable” by the North American
experts (Antman et al 2004) and “optional” by the European
experts (van de Werf et al 2003). Interestingly, since these
recommendations were established, a meta-analysis of UFH
trials in STEMI patients (including two trials using
streptokinase, one alteplase, and one anistreplase) showed
that intravenous UFH did not reduce death/reinfarction,
while increasing bleeding (Eikelboom et al 2005). There
was also a modest, non-significant excess of strokes in
patients treated with UFH, which was largely accounted for
by an increase in intracranial hemorrhages.
Because of their ease of administration, the predictability
of their anticoagulant effect, and the good results obtained
in patients with non-ST elevation acute coronary syndromes
(Eikelboom et al 2000), low-molecular-weight heparins have
been tested as a potentially valuable alternative to UFH in
STEMI patients. Compared with placebo, low-molecular-
weight heparins were shown to reduce reinfarction and
death, but at the expense of an increased bleeding risk
(Eikelboom et al 2005; Yusuf et al 2005). Compared with
UFH, they reduced reinfarction but not death, according to
a meta-analysis of various trials (Eikelboom et al 2005) and
the more recent ExTRACT-TIMI 25 study (Antman et al
2006); furthermore, they increased the bleeding risk. Thus,
in the North American guidelines, low-molecular-weight
heparins are considered as an alternative therapy to UFH in
patients below 75 years of age (Antman et al 2004). The
European guidelines give no recommendations regarding
these drugs, citing the need for additional studies (van de
Werf et al 2003). Of note, these recommendations were
issued before publication of the large ExTRACT-TIMI 25
study of enoxaparin. Another anticoagulant drug,
bivalirudin, a specific thrombin inhibitor, similarly reduced
reinfarction, but not death, and increased bleeding,
compared with UFH (White 2001).
Finally, in STEMI patients not undergoing reperfusion
therapy and with no contraindication to anticoagulation,
experts consider treatment with intravenous or subcutaneous
UFH for at least 48 hours to be reasonable (Antman et al
2004).
Fondaparinux, a new anticoagulant
Mechanism of action
Fondaparinux is the first drug of a new group of
anticoagulant compounds, the synthetic inhibitors of
activated factor X or factor Xa (Herbert et al 1997). It is a
single chemical entity (1728 Da) composed of 5 saccharides,
designed specifically to bind strongly and exclusively to
antithrombin. By binding to antithrombin, fondaparinux
increases the ability of antithrombin to inactivate factor Xa
by a factor of about 300 (Herbert et al 1997). Although
fondaparinux does not mediate the inhibition of coagulation
factors other than factor Xa, it effectively inhibits thrombin
generation (Béguin et al 1989). This inhibition is observed
even in the presence of platelets (Béguin et al 1989),
suggesting that fondaparinux may be effective for treating
arterial as well as venous thrombotic disorders.
Pharmacokinetics and
pharmacodynamics
The main pharmacokinetic characteristics of fondaparinux
after administration of a single subcutaneous dose of 2.5 mg,
the approved thromboprophylactic dose, are shown in Figure
1 (Donat et al 2002). On the whole, the subcutaneous
absorption of fondaparinux is rapid, complete, and
independent of the dose. Fondaparinux exerts very limitedVascular Health and Risk Management 2006:2(4) 373
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effects on routine hemostasis tests. Fondaparinux is almost
completely excreted by the kidneys. The intra-subject and
inter-subject variability of its pharmacokinetics is narrow,
eliminating the need for dose adjustments and routine
coagulation monitoring in the majority of patients.
Furthermore, interaction between fondaparinux and several
other commonly used drugs, including aspirin, is unlikely
(Turpie 2005).
Prevention of venous thromboembolism
A single dose of fondaparinux, 2.5 mg once daily
administered subcutaneously, was used in all trials in the
prevention of venous thromboembolism, regardless of
patient, surgical, or medical characteristics. This dose was
selected on the basis of a phase II study in patients
undergoing total hip replacement (Turpie et al 2001).
Compared with reference comparators, once-daily 2.5 mg
fondaparinux was highly effective. In patients undergoing
major orthopedic surgery, fondaparinux reduced the
incidence of venous thromboembolism by more than 50%
(p<0.001) compared with the low-molecular-weight heparin,
enoxaparin (Bauer et al 2001; Eriksson et al 2001; Lassen
et al 2002; Turpie et al 2002a, 2002b). In patients undergoing
high-risk abdominal surgery, once-daily 2.5 mg
fondaparinux reduced the incidence of venous
thromboembolism by 25.8% compared with dalteparin
(p=0.14) (Agnelli et al 2005). In acutely ill medical patients
with restricted mobility, once-daily 2.5 mg fondaparinux
reduced the incidence of venous thromboembolism by
46.7% compared with placebo (p=0.029) (Cohen et al 2006).
In all these trials, the safety of fondaparinux in terms of
bleeding risk, when used as recommended (notably with
the first administration at least 6 hours after surgical closure),
was comparable with that of the reference products (Turpie
2005). In acutely ill medical patients, the incidence of major
bleeding in both the fondaparinux and placebo groups was
very low (0.2%) (Cohen et al 2006). Furthermore, no
immuno-allergic thrombocytopenia was reported.
Fondaparinux did not show any liver toxicity (Turpie 2005).
Treatment of venous thromboembolism
The clinical benefit of fondaparinux in the treatment of
venous thromboembolism was demonstrated in 2
randomized, non-inferiority trials (called MATISSE). In
these trials, fondaparinux was at least as effective as
enoxaparin or UFH in the treatment of patients with deep-
vein thrombosis or pulmonary embolism, respectively
(Buller et al 2003, 2004). In this indication, the once-daily
dose of fondaparinux was 7.5 mg (adjusted to 5 mg for
patients with a body weight less than 50 kg and 10 mg for
those with a body weight greater than 100 kg).
Treatment of patients with unstable
angina or non-STEMI
The efficacy and safety of fondaparinux in the management
of patients with non-STEMI coronary syndromes were
investigated in the randomized, double-blind, non-inferiority
OASIS-5 trial performed in 20 078 patients (Yusuf et al
2006a). Fondaparinux was administered subcutaneously at
the once-daily dose of 2.5 mg. The reference comparator
was enoxaparin administered at the approved subcutaneous
dose  of  1 mg/kg  twice  daily;  the  dose  was  reduced  to
1 mg/kg once daily in patients with renal impairment as
recommended. Both study treatments were administered for
a mean of 5 days.
At day 9, fondaparinux was non-inferior to twice-daily
enoxaparin, in terms of preventing death, myocardial
infarction (MI), or refractory ischemia (5.9% in
fondaparinux-treated patients vs 5.8% in enoxaparin-treated
patients; hazard ratio: 1.01; 95% confidence interval: 0.90–
1.13, below the prespecified boundary of 1.185; p=0.007
for non-inferiority) (Figure 2). This result was consistent in
all subgroups studied, including patients undergoing PCI.
The rate of major bleeding was reduced by 48% (p<0.001)
in the group of patients treated with fondaparinux (2.2% vs
4.1%). This result was observed in most subgroups, but the
reduction in bleeding was greater in patients not undergoing
revascularization procedures within 9 days following the
index event (p<0.001). The reduction in major bleeding was
also observed in patients with a creatinine clearance below
30 mL/min (2.4% vs 9.9%, p<0.001). Importantly, the lower
rate of bleeding was associated with a significant reduction
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Figure 1 Pharmacokinetics of fondaparinux administered at the subcutaneous
dose of 2.5 mg. Drawn from data of Donat et al (2002).
Abbreviations: Cmax, peak plasma concentration; tmax, time to peak plasma
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in the long-term risk of death, at one month by 17% (p=0.02),
and at 6 months by 11% (p=0.05), confirming the
relationship bleeding/long-term prognosis. Overall,
fondaparinux presented a significantly (p<0.001) better
benefit-to-risk ratio (defined as the composite of death, MI,
refractory ischemia or major bleeding) up to 6 months after
the index coronary event.
Fondaparinux in STEMI
The benefit of fondaparinux in the management of patients
with STEMI was evaluated in the recently completed
OASIS-6 trial (Yusuf et al 2006b). The OASIS-6 trial was a
phase III, multicenter, randomized, double-blind, controlled,
parallel-group trial of fondaparinux vs standard therapy in
patients with confirmed STEMI (Figure 3). The aim of the
trial was to demonstrate the superiority of fondaparinux vs
standard therapy in terms of antithrombotic efficacy, with
no increase in bleeding risk.
This was a very pragmatic trial performed in a broad
range of patients with STEMI, ie, patients receiving either
thrombolytic drugs, or primary PCI, or no revascularization
treatment. Accordingly, randomization was stratified by
indication for the use of UFH based on the investigator’s
judgment. Patients with no indication for UFH were enrolled
in stratum 1, patients with indication for UFH being enrolled
in stratum 2. Patients with an indication for UFH included
patients in whom use of fibrin-specific thrombolytic drugs
was intended, patients not eligible for thrombolytics but
eligible for antithrombotics, and patients scheduled for
primary PCI.
As in OASIS-5, the dose of fondaparinux was 2.5 mg
once daily. This dosage regimen was chosen on the basis of
data obtained in dose-ranging trials in patients with acute
coronary syndromes, including patients with STEMI
(Coussement et al 2001; Simoons et al 2004; Mehta et al
2005). Thus, patients in stratum 1 were assigned to receive
either fondaparinux 2.5 mg or matching placebo once daily
intravenously the first day, then subcutaneously on
subsequent days for up to 8 days or hospital discharge if
earlier. Patients in stratum 2 not scheduled for primary PCI
were assigned to receive either fondaparinux 2.5 mg once
daily (intravenously the first day, then subcutaneously on
subsequent days) for up to 8 days or hospital discharge if
earlier, or intravenous UFH for up to 48 hours as
recommended. Patients in stratum 2 scheduled for primary
PCI received single-bolus injections of either fondaparinux
or UFH immediately before the procedure, the dose given
depending on whether UFH and glycoprotein IIb/IIIa
antagonists had been administered pre-randomization.
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Figure 2 Main results of the OASIS-5 trial. Drawn from data of Yusuf et al
(2006a).
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The primary efficacy outcome was the composite of
death or recurrent MI up to day 30. The primary safety
outcome was severe bleeding up to day 9. All deaths,
reinfarction, and severe hemorrhage were centrally
adjudicated using standardized definitions. The duration of
follow-up was 180 days.
Initially, a sample size of 10 000 patients was planned,
based on an event rate for death or reinfarction of about 8%
at day 9. This sample size allowed detection of a relative
risk reduction of 20% (two-sided alpha = 0.05), with a power
of 90%. As the overall (blinded) event rate in the first 8000
randomized patients was lower than originally expected,
the Steering Committee recommended two modifications:
first, to ascertain the primary efficacy outcome at day 30
(instead of day 9); second, to increase the sample size to
12 000 patients. All analyses were performed according to
the intention-to-treat principle.
A total of 12 092 patients were randomized. A
thrombolytic drug was administered to 45% (n=5436) of
patients, and primary PCI was performed in 31% (n=3789);
24% (n=2867) did not have any revascularization procedure.
The thrombolytic drug was streptokinase in 73% of patients.
After randomization, more than 95% of patients were treated
with aspirin, and about 60% of patients received clopidogrel.
At day 30, fondaparinux significantly (p=0.008) reduced
the occurrence of the primary efficacy outcome (death or
recurrent MI) by 14%, from 11.2% in the control group to
9.7% (Figure 4). Consistent reductions in both death and
recurrent MI emerged at day 9 and were observed up to 6
months after the cardiac event. At 6 months, mortality was
reduced (p=0.03) by 12% in the fondaparinux group (Figure
5): this result mainly concerned cardiac deaths. The rate of
stroke was comparable between the two groups (0.7% in
the fondaparinux group and 0.9% in the control group). The
effect of fondaparinux on the composite outcome of death
or recurrent MI was not statistically heterogeneous between
the two strata. It was consistent irrespective of gender, age,
time from symptom onset to randomization, use of pre-
randomization UFH, or type of thrombolytic agent
administered. Significant benefits were observed in patients
who received no reperfusion therapy or a thrombolytic agent,
but not in patients undergoing primary PCI (Figure 6).
Although, as in OASIS-5 (Yusuf et al 2006a), a higher rate
of guiding catheter thrombosis was observed with
fondaparinux when PCI was performed without UFH, this
was largely avoided if UFH was used before the procedure.
Thus, in patients undergoing non-primary PCI in whom
UFH was recommended before the procedure, there was no
catheter thrombosis in either study group. There was a non-
significant (p=0.13) trend towards fewer severe bleeds in
Figure 3 Study design of the OASIS-6 trial. Drawn from data of Yusuf et al (2006b).
Abbreviations: i.v., intravenously; od, once daily; RPA, reteplase; SK, streptokinase; TNK, tenecteplase; TPA, alteplase; s.c., subcutaneously; STEMI, ST-segment elevation
myocardial infarction; UFH, unfractionated heparin.
Patients with STEMI Patients with STEMI Patients with STEMI
Thrombolytics (SK, TPA, TNK, RPA), 
Primary PCI or no reperfusion
Randomization Randomization
Stratum 1
UFH not indicated
Stratum 2
UFH Indicated
Fondaparinux s.c. 
2.5 mg od/8 days
Placebo
8 days
UFH i.v. 
24-48 h
Fondaparinux s.c. 
2.5 mg od/8 days
Figure 4 Primary efficacy results of the OASIS-6 trial. Drawn from data of Yusuf
et al (2006b).
Abbreviations: CI, confidence interval; HR, hazard ratio; UFH, unfractionated
heparin.
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the fondaparinux group (1.0%) compared with the control
group (1.3%) (Table 1).
Overall, throughout the study period, the balance of
benefit and risk defined by the composite of death, recurrent
MI, or severe bleeding was in favor of fondaparinux.
Place of fondaparinux compared
with other anticoagulants in
patients with STEMI
No trials similar to OASIS-6, encompassing such a broad
range of clinical conditions, have been performed with other
anticoagulant drugs. Thus, in order to better appraise the
value of fondaparinux relative to other anticoagulant drugs,
the data need to be analyzed according to various specific
settings, notably the type of reperfusion administered to the
patient.
In STEMI patients treated with a thrombolytic drug,
fondaparinux significantly reduced death and reinfarction
by 21% and severe bleeding by 34% as compared with
standard treatment (Figure 6A). In the same context, low-
molecular-weight heparins were shown to increase bleeding,
Figure 5 Mortality in the OASIS-6 trial. Drawn from data of Yusuf et al (2006b).
Abbreviations: CI, confidence interval; HR, hazard ratio; UFH, unfractionated
heparin.
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Figure 6 Results according to the type of reperfusion therapy in OASIS-6.
Drawn from data of Yusuf et al (2006b).
Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not available; PCI,
percutaneous coronary intervention; UFH, unfractionated heparin.
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Table 1 Bleeding events in the OASIS-6 trial
Fondaparinux Placebo or Hazard ratio p value 
N=6036 unfractionated (95% confidence
n (%) heparin interval)
N=6056
n (%)
Total 61 (1.0) 79 (1.3) 0.77 (0.55–1.08) 0.13
Fatal 35 (0.6) 49 (0.8) 0.72 (0.47–1.10) 0.13
Intracranial hemorrhage 11 (0.2) 10 (0.2) 1.10 (0.47–2.60) 0.82
Cardiac tamponade 28 (0.5) 48 (0.8) 0.59 (0.37–0.93) 0.02
Stratum 1 (vs placebo)
Total 28 (1.0) 44 (1.6) 0.63 (0.40–1.02) 0.06
Stratum 2 (vs unfractionated heparin)
Total 33 (1.1) 35 (1.1) 0.95 (0.59–1.52) 0.82Vascular Health and Risk Management 2006:2(4) 377
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either vs placebo (Yusuf et al 2005) or UFH (ASSENT 2001;
Antman et al 2006); furthermore, in the latter situation, low-
molecular-weight heparins reduced recurrent myocardial
infarction, but not death. Data suggesting an adverse effect
of enoxaparin on bleeding were obtained even in trials in
which dosing strategy was adjusted according to the patient’s
age and renal function (Antman et al 2006). Similar results
were found with bivalirudin vs UFH (White 2001). Thus,
fondaparinux could become the new standard anticoagulant
drug in patients with STEMI treated with thrombolytic
drugs. The benefit of fondaparinux in patients treated with
fibrin-specific thrombolytic should nevertheless be
confirmed in a larger sample of patients.
In STEMI patients treated with PCI, fondaparinux was
no more effective or safe than standard treatment (Figure
6B). The specific role of low-molecular-weight heparins in
the invasive management of STEMI has not yet been
established. Indeed, most trials which have investigated the
role of these drugs during PCI were performed in patients
undergoing elective angioplasty or PCI for unstable angina
or non-STEMI. Thus, in patients with STEMI undergoing
primary PCI, UFH remains the standard therapy (Silber et
al 2005; Smith et al 2006). The OASIS-6 data on
fondaparinux are unlikely to prompt any change in this
recommendation. However, the administration of
fondaparinux after PCI may be valuable. In OASIS-6
patients undergoing primary PCI, there were fewer deaths
or cases of reinfarction between 3 and 9 days after
randomization in the fondaparinux group (1.4%) compared
with the control group (2.0%) (Yusuf et al 2006b).
The group of STEMI patients not undergoing PCI or
not receiving thrombolytic drugs is substantial. In OASIS-
6, it represented 24% of the overall population. Likewise,
registry data indicate that 25%–30% of eligible patients with
STEMI never receive thrombolytic drugs and do not undergo
early PCI (Eagle et al 2002). In this context, fondaparinux
may represent a new reference anticoagulant drug, since it
reduced the incidence of death/reinfarction without
increasing severe bleeding (Figure 6C). In comparison,
reviparin reduced death/reinfarction/stroke compared with
placebo in patients enrolled in the CREATE study who did
not receive any reperfusion treatment (21% of the overall
population) (Yusuf et al 2005). Data on bleeding events in
this subgroup were not given, but overall, reviparin
increased the rate of major bleeding. In the TETAMI trial,
enoxaparin was not superior to UFH in STEMI patients not
eligible for reperfusion (Cohen et al 2003).
Conclusion
The OASIS-6 study showed that, unlike other anticoagulant
agents, fondaparinux significantly reduced mortality among
patients with STEMI, without increasing severe bleeding.
These results were consistent vs either placebo or UFH,
especially during long-term follow-up. The benefit of
fondaparinux was marked in patients receiving
thrombolytics, with a lower rate of major bleeding.
Fondaparinux was also beneficial in patients undergoing
no reperfusion therapy. However, fondaparinux showed no
benefit in patients undergoing primary PCI.
Overall, the OASIS data (OASIS-5 and OASIS-6)
obtained in about 32 000 patients with acute coronary
syndromes showed that fondaparinux preserved or even
improved the benefits of conventional anticoagulant drugs,
while reducing bleeding (Yusuf et al 2006a, 2006b).
Importantly, the safety data in terms of bleeding risk
translated into improved long-term mortality and morbidity.
These data were obtained with a single dosage regimen of
2.5 mg once daily. The absence of dose adjustments
according to indication may also facilitate the use of this
drug in routine practice and limit dosing errors associated
with a risk of bleeding or death (Alexander et al 2005).
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